Syngen AI Technologies AB takes 0.2% stake in CellVoyant Technologies, an AI cell-therapy technology firm
Published
Syngen AI Technologies AB has entered CellVoyant Technologies Limited’s register with 58,394 ordinary shares, representing a 0.2% stake. The increase in total shares suggests fresh funding for the company. The statement was filed on 9 September 2026, covering the period from 30 August 2025 to 30 August 2026.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| Exited | VERVE INVESTMENT SYNDICATES GMBH | 859,375 | — | SERIES SEED 2 859,375 |
| Exited | AIR STREET CAPITAL I (GP) LLP AS GENERAL PARTNER OF AIR STREET CAPITAL I LP | 0 | — | SERIES SEED 0 SERIES SEED 2 0 |
| New shareholder | VERVE CAPITAL PARTNERS AG (MERGED WITH VERVE INVESTMENT SYNDICATES GMBH) | 859,375 | — | SERIES SEED 2 859,375 |
| New shareholder | SYNGEN AI TECHNOLOGIES AB | 58,394 | — | ORDINARY 58,394 |
Current shareholders (11)
| Shareholder | Total shares | Share classes |
|---|---|---|
| AIR STREET CAPITAL I GP LTD. | 3,977,658 | SERIES SEED 3,915,158 SERIES SEED 2 62,500 |
| OCTOPUS TITAN VCT PLC | 3,888,105 | SERIES SEED 2 3,888,105 |
| DEBUSSY INTERNATIONAL LIMITED | 3,125,000 | SERIES SEED 2 3,125,000 |
| OCTOPUS INVESTMENTS NOMINEES LIMITED | 3,017,169 | SERIES SEED 2 3,017,169 |
| COMPOUND 2021, L.P. | 1,195,468 | SERIES SEED 1,195,468 |
| UNIVERSITY OF BRISTOL | 944,000 | ORDINARY 944,000 |
| OCTOPUS FUTURE GENERATIONS VCT PLC | 907,225 | SERIES SEED 2 907,225 |
| VERVE CAPITAL PARTNERS AG (MERGED WITH VERVE INVESTMENT SYNDICATES GMBH) | 859,375 | SERIES SEED 2 859,375 |
| ETERNAL BLISS LIMITED | 747,167 | SERIES SEED 747,167 |
| LISALIS GMBH | 119,547 | SERIES SEED 119,547 |
| SYNGEN AI TECHNOLOGIES AB | 58,394 | ORDINARY 58,394 |
Contact the editorial team at editorial@fundingspotter.com